NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
12/16/2022
Back to search
Official data from USPTO
MOLECULAR CANCER THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MOLECULAR CANCER THERAPEUTICS
ST13
US500000076051350Class
16, 42
Filing
76051350
Registration
2596253
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
12/16/2022
Trademark type
Word
Nice classes
16, 42
Filing date
05/18/2000
Registration date
07/16/2002
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/16/2022
Last transaction
12/16/2022
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
10/30/2001
First use in commerce
10/30/2001
Drawing code
1
Owner type
99
Owner location
Philadelphia, PA, US
Examiner
LOTT, MAUREEN
Law office
M10
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
American Association for Cancer Research, Inc.
Representatives
Mark A. Steiner, Esq. Duane Morris LLP
Technical classification
Nice Classes
Class 16Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 16
Publicationsnamely journals in the field of medicine
Class 42
Online publicationsjournals in the field of medicine; and computer servicesproviding online news and information in the field of medicine
Publications
History of USPTO decisions and trademark events.
37 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
12/16/2022
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
12/16/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/16/2022
E89R
TEAS SECTION 8 & 9 RECEIVED
06/02/2022
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
07/16/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/03/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/03/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/03/2012
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/03/2012
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
07/27/2011
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
07/27/2011
E89R
TEAS SECTION 8 & 9 RECEIVED
07/19/2011
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/29/2010
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/25/2010
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
08/05/2008
ES8R
TEAS SECTION 8 RECEIVED
07/15/2008
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/11/2008
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/11/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/11/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/11/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/09/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/09/2008
CFIT
CASE FILE IN TICRS
10/25/2007
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
07/16/2002
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
04/01/2002
IUAA
USE AMENDMENT ACCEPTED
04/01/2002
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
03/20/2002
IURF
IU INFORMAL RESPONSE RECEIVED
03/08/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/08/2002
IUFF
USE AFFIDAVIT FAILED FORMALITIES
03/04/2002
IUAF
USE AMENDMENT FILED
01/09/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/09/2002
CNFR
FINAL REFUSAL MAILED
07/19/2001
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/21/2001
CNRT
NON-FINAL ACTION MAILED
11/29/2000
DOCK
ASSIGNED TO EXAMINER
10/27/2000
Continuous trademark protection
Get notified about every new filing that threatens MOLECULAR CANCER THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.